Director and Professor
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine and Director of Nanotechnology and Regenerative Medicine Company has worked at Royal Free Hospital and University College London over 25 years, published over 647 peer-reviewed research papers, edited 2 books and contributed to 39 book chapter, and 14 UK and International patents. He is currently director of NanoRegMed Ltd, working in commercialisation of his research. During his career he has led and managed many large projects with multidisciplinary teams with very successful outcomes in terms of commercialisation and translation to patients including 1) The development and commercialisation of a bypass graft for vascular access for haemodialysis; 2) The development of bioreactors with fluid dynamic systems; 3) Non-invasive techniques to monitor viscoelastic properties of cardiovascular system and many others. He was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants in 2007 by Medical Future Innovation, and in 2009 received a Business Innovation Award from UK Trade & Investment (UKTI) in the Life Sciences and Healthcare category. European Life Science Awards. Winner of most innovative new product 2012 “Synthetic Trachea”. Hamburg, Germany, 29 may 2012. He also was awarded Nanosmat Prize in August 2013 in Spain for his achievements and contributions to Nanoscience and nanotechnology. In 2016 in Brussels he received the Heals distinguish research award in recognition for his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. He developed world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials and bioactive molecules and stem cells technology. He has created a huge amount of media interest for his translational research work to first in man, including; world first synthetic trachea, bypass graft, lacrimal duct, and other surgical implants.
Development of Nanomaterial,cardiovascular implant,nanofluorescence particle including quantum dots for localisation and treatment of cancer,Stem cells for development of organ using tissue engineering. Development of organ using biodegradation nanomaterials and stem cells, including liver, intestine,Hepatic microcirculation and oxygenation using optical technique,Ischemia reperfusion injury and preconditioning.